Moderate

Childhood obesity

endocrine · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

BMI at or above the 95th centile (or 98th centile on UK charts) for age and sex. The overwhelming majority is lifestyle-related; assessment screens for rare endocrine/syndromic causes and for comorbidities.

Red flags

  • Obesity with short stature or slowing height velocity (endocrine cause)
  • Developmental delay or dysmorphic features (syndromic cause)
  • Rapid weight gain with signs of Cushing or hypothalamic lesion
  • Symptoms of OSA, SUFE (hip/knee pain), or severe hypertension

Assessment

Differential diagnosis

  • Exogenous (lifestyle) obesity (vast majority)
  • Hypothyroidism
  • Cushing syndrome / exogenous steroids
  • Monogenic obesity (e.g. MC4R, leptin pathway)
  • Syndromic obesity (Prader-Willi, Bardet-Biedl)
  • Growth hormone deficiency
  • Hypothalamic obesity (post tumour/surgery)

Investigations

  • BMI centile and trend plotted on age/sex charts, waist circumference
  • Blood pressure using appropriate cuff
  • Fasting glucose/HbA1c and lipid profile in those at risk
  • LFTs for non-alcoholic fatty liver disease
  • TFTs and other endocrine tests only if short/slowing growth or clinical pointers
  • Genetic testing if early severe obesity, developmental delay or dysmorphism

Management

  • Confirm obesity using BMI centile and assess growth velocity
  • Red-flag pathological causes: short stature, slowing growth, dysmorphism, developmental delay
  • Take diet, activity, screen-time, sleep and family history
  • Screen for comorbidities (hypertension, dyslipidaemia, dysglycaemia, NAFLD, OSA, orthopaedic)
  • Assess psychosocial factors, mood and signs of disordered eating
  • Deliver family-based lifestyle intervention (diet, activity, behaviour, screen-time)
  • Treat identified comorbidities and refer for OSA/orthopaedic concerns
  • Consider specialist tier for severe/complex obesity (pharmacotherapy/bariatric assessment in adolescents)
  • Arrange regular supportive follow-up avoiding stigmatising language

Drugs & doses

No first-line drug; lifestyle change is the foundation of treatment
GLP-1 receptor agonists (e.g. liraglutide/semaglutide) in specialist adolescent services for selected cases
Orlistat occasionally used in adolescents under specialist supervision
Treat comorbidities (e.g. metformin for impaired glucose tolerance) per specialist

Disposition

Primary care/community lifestyle programmes; refer to specialist weight-management/endocrine service for red flags, severe obesity, or comorbidities.

Complications & pitfalls

  • Type 2 diabetes and dyslipidaemia
  • Non-alcoholic fatty liver disease and hypertension
  • Obstructive sleep apnoea and slipped upper femoral epiphysis
  • Psychological harm, bullying and low self-esteem

Exam pearls

  • Obesity with declining height velocity suggests an endocrine cause and warrants investigation
  • Most endocrine causes are associated with short, not tall, stature
  • Family-based lifestyle change is more effective than targeting the child alone
  • Use sensitive, non-stigmatising language with the child and family

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.